Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer

University of British Columbia

Status and phase: Terminated; Phase 3; Phase 2

Conditions: Breast Cancer

Treatments: Drug: Eplerenone; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01708798

H12-00185

Details and patient eligibility

About

Doxorubicin and other anthracyclines are commonly used to treat breast cancer and other types of cancer. Unfortunately, they can cause heart muscle damage, resulting in scarring, abnormal contraction and relaxation, and heart failure symptoms. This side effect occurs more frequently at higher doses, and limits the total dose that can be given to cancer patients. Eplerenone is an oral medication that prevents or reverses heart damage in other disease states, and is commonly used to treat heart failure. This study will investigate the use of eplerenone to protect the heart from these harmful side effects of doxorubicin.

Few therapies have been shown to prevent heart damage in patients receiving anthracyclines. Small studies have suggested that other heart failure medications (ACE inhibitors, beta-blockers) may reduce the incidence of cardiac toxicity, but eplerenone and other drugs in its class (aldosterone antagonists) have not previously been studied. Eplerenone inhibits enzyme pathways that cause scarring of the heart, and animal studies suggest that anthracyclines cause damage through these same pathways.

This study aims to investigate whether eplerenone protects the heart from the harmful effects of doxorubicin chemotherapy. Specifically, it will measure the effect that eplerenone has on heart muscle relaxation. It will randomly assign women undergoing chemotherapy with doxorubicin to one of two groups: one group will receive eplerenone, and the other group will receive placebo (sugar) pills. The subjects will not know which type of pills they are taking. Heart muscle relaxation will be measured at baseline, after completion of chemotherapy (8-12 weeks), and after 6 months. There will also be various blood tests measured in the study subjects, to determine whether there might be certain blood tests that identify patients at particularly high risk of heart toxicity after doxorubicin therapy.

Enrollment: 44 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage I-III breast cancer
• Scheduled to undergo treatment with doxorubicin-based chemotherapy regimen
• Able to provide informed consent

Exclusion criteria

• Use of anthracycline agents other than doxorubicin
• Baseline LVEF ≤50% by any modality (nuclear, echo, MRI)
• Atrial fibrillation or flutter
• Mitral valve disease (More than mild mitral stenosis or regurgitation, previous mitral valve replacement or repair)
• Inability to obtain adequate echo images for required analysis
• Hyperkalemia (K+ >5.0)
• Glomerular filtration rate (GFR) <30 ml/min/1.73m2
• Uncontrolled hypertension, defined as having a systolic blood pressure > 180 mmHg and/or a diastolic blood pressure >110 mmHg
• Symptomatic hypotension or systolic blood pressure <85 mmHg
• History of hypersensitivity to eplerenone or spironolactone
• Significant hepatic disease (e.g., previously documented positive serology for viral hepatitis) or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 times the upper limits of normal
• Concomitant treatment with spironolactone, potassium-sparing diuretics, potassium supplements, or strong inhibitors of cytochrome P450 3A4 (CYP3A4) (i.e. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir)
• History of alcohol and/or any other drug abuse
• Women who are either pregnant, lactating or of childbearing potential and not using an acceptable method of contraception
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

44 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

One tablet by mouth daily. If serum potassium level is \<5.0 mmol/L at four weeks, increase to two tablets by mouth daily. If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is \<5.0 mmol/L at four weeks, increase to one tablet by mouth daily.

Treatment:

Drug: Placebo

Eplerenone

Experimental group

Description:

Eplerenone 25 mg tablet by mouth daily. If serum potassium level is \<5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily. If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is \<5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily.

Treatment:

Drug: Eplerenone